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Abstract
The vast majority of connections between complex disease and common genetic variants were
identified through meta-analysis, a powerful approach that enables large sample sizes while
protecting against common artifacts due to population structure, repeated small sample analyses,
and/or limitations with sharing individual level data. As the focus of genetic association studies
shifts to rare variants, genes and other functional units are becoming the unit of analysis. Here, we
propose and evaluate new approaches for performing meta-analysis of rare variant association
tests, including burden tests, weighted burden tests, variable threshold tests and tests that allow
variants with opposite effects to be grouped together. We show that our approach retains useful
features of single variant meta-analytic approaches and demonstrate its utility in a study of blood
lipid levels in ∼18,500 individuals genotyped with exome arrays.
Introduction
Proceeding from the discovery of a genetic association signal to a mechanistic insight about
human biology should be much easier for one or a set of alleles with clear functional
consequence, including non-synonymous, splice altering and protein truncating alleles. Most
of these alleles are very rare, with only one such allele expected to reach MAF>5% in the
average human gene1. Recent advances in exome sequencing and the development of exome
genotyping arrays are enabling explorations of the very large reservoir of rare coding
variants in humans and are expected to accelerate the pace of discovery in human genetics2.
Rare variants can be examined using association tests that group alleles in a gene or other
functional unit3. Compared to tests of individual alleles, this grouping can increase power,
especially when applied to large samples where several rare variants are observed in the
same functional unit4. The simplest rare variant tests consider the number of potentially
functional alleles in each individual5, but the tests can be refined to weigh variants according
to their likely functional impact6, to allow for imputed or uncertain genotypes7,8, or to allow
variants that increase and decrease risk to reside in the same gene9-11 (a feature that is
important when the same gene harbors hypermorph and hypomorph alleles12). The optimal
strategy for grouping and weighting rare variants – ranging from focusing on protein
truncation alleles to examining all non-synonymous variants and encompassing strategies
that examine all variants with frequency <5% as well as alternatives that examine only
singletons – depends on the unknown genetic architecture of each trait and each locus13.
Here, we describe practical approaches for meta-analysis of rare variants. Our approach
starts with simple statistics that can be calculated in an individual study (single site score
statistics and their covariance matrix, which summarizes the linkage disequilibrium
information and relatedness among sampled individuals). We then show that, when these
statistics are shared, a wide variety of gene-level association tests can be executed centrally
– including both weighted or un-weighted burden tests with fixed5 or variable frequency
threshold6 and sequence kernel association tests (SKAT) that accommodate alleles with
opposite effects within a gene9. Our approach generates comparable results to sharing
individual level data (and, in fact, identical results when allowing for between study
heterogeneity in nuisance parameters, such as trait means, variances and covariate effects).
As an illustration of our approach, we analyze blood lipid levels in >18,500 individuals
genotyped with exome genotyping arrays. Our analysis of blood lipid levels provides
examples of loci where signal for gene-level association tests exceeds signal for single
variant tests and shows that our approach can recover signals driven by very rare variants
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variant association studies, we expect our methods (and refined versions thereof) will be
widely useful.
Our approach is based on the insight that analogues of most gene level association tests can
be constructed using single variant test statistics and knowledge of their correlation
structures. As shown in Methods, simple14 and weighted10,15 burden tests, variable
threshold tests6 and tests allowing for variants with opposite effects9 can be constructed in
this manner. We meta-analyze single variant statistics using the Cochran-Mantel-Haenszel
method, calculate variance-covariance matrices for these statistics, and construct gene-level
association tests by combining the two. In Supplementary Notes, we show that rare variant
statistics generated in this way are identical to those obtained by sharing individual level
data and allowing for heterogeneity in nuisance parameters, with no loss of power.
Importantly, rare variant statistics calculated in this way are less vulnerable to artifacts due
to population stratification than statistics generated by naïvely pooling individual level data.
As in other meta-analysis settings, sharing summary statistics accelerates the overall
analysis process, mitigates concerns about participant confidentiality, and reduces the risk
that data will be used for unapproved analyses (as always, to avoid violating the trust of
research subjects, we strongly recommend that investigators sharing summary statistics
agree that these will not be used to identify research subjects). For evaluating significance,
we propose methods for calculating p-values using asymptotics and also Monte-Carlo
methods that use knowledge of linkage disequilibrium relationships to sample plausible
combinations of single variant statistics and then generate empirical distributions for our
gene-level statistics. Since evaluating asymptotic p-values can be numerically unstable,
Monte-Carlo methods can be used to verify interesting p-values.
Results
We first evaluated our method using simulations. Genes were simulated as stretches of 5,000
base-pairs using the coalescent16 and a demographic model (including an ancient bottleneck,
recent exponential growth, differentiation and migration) calibrated to mimic a sample of
multiple European populations17,18 (Supplementary Figure 1 and Supplementary Notes).
The average FST value between simulated populations was 0.004 – as expected when the
distribution of rare variants is geographically restricted19. The simulations produced samples
of 1,000 individuals, each drawn from one of several related populations, typically including
a few shared variants and many population specific variants. Half of the simulated variants
were randomly set to increase trait values by 1/8th of a standard deviation (Supplementary
Figure 2 and see Supplementary Figure 3 and 4 for similar results using alternative trait
models).
We analyzed each simulated sample with a series of gene-level association tests.
Supplementary Figures 2-4 compare results obtained for 10,000 simulated genes using our
meta-analysis approach to a combined analysis of individual level data across studies. For
variable threshold tests, we found the p-values were sometimes slightly different (r2=0.995
between the two sets of log p-values); for the other two tests p-values and test statistics were
indistinguishable. Calculation of analytical p-values for variable threshold tests requires the
evaluation of high-dimensional integrals that can be numerically unstable and is thus very
sensitive to small differences in the variance-covariance matrix. In practice, it will often be a
good idea to confirm significant p-values using our Monte-Carlo approach.
To evaluate our Monte-Carlo approach, we compared its empirical p-values to those
obtained by permuting phenotypes between individuals within each study. We implemented
adaptive versions of both algorithms20, with more simulations carried out when the p-value
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tis small and fewer simulations when the p-value is large. Log p-values for the two
approaches are highly concordant (r2=0.996). When small p-values are estimated, increasing
the number of simulations improves the precision for the estimated p-values (Supplementary
Figure 5).
We next verified type I error was well controlled (Supplementary Table 1). In all analyses,
we first applied an inverse normal transformation to trait residuals (which helps ensure our
statistics are well behaved even for very rare variants, as in Supplementary Figure 6).
Reassured that type I error was well controlled, we next explored power for several
scenarios (Figure 1A, 1B, 1C and Supplementary Figure 7A, 7B, 7C). It is clear that, for the
effect sizes simulated here, very large samples may be required. In some settings, power
only reaches ∼60% in analyses of ∼100,000 individuals. We did not find a universally most
powerful method, emphasizing the value of implementing a diverse set of test statistics (see
also Ladouceur et al13). Since meta-analysis methods that combine p-values are popular for
common variants and can also be implemented for rare variants, we compared power
between our method and analyses based on Fisher's method and the minimal p-value
approach for combining p-values (Figure 1 and Supplementary Figure 7). In all the
simulation scenarios considered, our method greatly outperforms these alternatives,
especially when information is combined across a large number of samples. In addition to
power, our approach provides three useful features. First, it provides great flexibility in the
choice of rare variant association test (definition of functional units, choice of variants to be
grouped, frequency thresholds for analysis); approaches based on Fisher's method would
likely require every contributing study to re-analyze their data when any of these changes.
Second, because in addition to p-values it provides for estimates of effect size (in all cases)
and allele frequency thresholds for candidate variants (in the variable threshold test), our
method provides rich information that helps interpretation. Third, our approach allows the
relationship between multiple association signals in a region to be dissected through
conditional analysis, as detailed below.
We proceeded to a meta-analysis of blood lipid levels in 18,699 individuals of European
ancestry genotyped with Illumina Exome arrays and drawn from 7 studies: the Women's
Health Initiative21, the Ottawa Heart Study22, the Malmö Diet and Cancer Study –
Cardiovascular Cohort (MDC)23, the PROCARDIS Precocious Coronary Artery Disease
Case Series, PROCARDIS Control series24 and the Nord-Trøndelag Health Study (HUNT)
myocardial infraction cases and matched controls25 (see Supplementary Table 2 and 3 for
summary statistics for each of these samples, including basic demographics, summaries of
lipid levels, number of non-synonymous and loss-of-function variants per individual and of
variants sites shared across different studies). Overall, 171,193 variants were polymorphic in
at least one individual. Among these variants, 125,702 – the vast majority – have frequency
<1%.
To verify the soundness of our approach, we repeated our power and type I error simulations
using real genotype data from the HUNT and MDC studies but simulated phenotypes. These
additional experiments confirm that our method produces well-calibrated statistics and is
more robust to stratification than analyses that directly pool individual level data and treat
the complete dataset as a single study without modeling heterogeneity between studies
(Supplementary Figure 8). In addition, the power for our method continued to exceed that
for alternatives that directly combine p-values from individual studies (Supplementary
Figure 9).
We then proceeded to meta-analyze single variant association test results. The resulting test
statistics appear well calibrated, with genomic control value <1.05 for all three traits, both
for common and for rare variants (Supplementary Figure 10). At a significance threshold of
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tp<3×10-7 (corresponding to 0.05/171,193), we found significantly associated variants (with
MAF<5%) at LPL26, ANGPTL426, LIPG26, CD300LG27, LIPC26, APOB26, HNF4A26 for
HDL; PCSK926, BCAM-CBLC-PVR (neighboring APOE)26, and APOB26 for LDL;
ANGPTL426, LPL26 and APOB26 for TG (Supplementary Table 4). Except for the variants
in LIPC and APOB, all other significantly associated variants have frequency of >1%
reflecting the limited power of single variant association tests for rare alleles.
We next carried out gene-level tests. Again, test statistics appear well calibrated, with
genomic control value <1.05 (Supplementary Figure 11). At a significance threshold of p
<3.1×10-6 (corresponding to 0.05/16,153 and thus allowing for the number of genes tested),
we observed association at LIPC, LPL, ANGPTL4, LIPG, HNF4A and CD300LG for HDL,
at the PCSK9, APOE-locus (as well as nearby genes PVR, BCAM, and CBLC), and LDLR
for LDL, and at ANGPTL4, and LPL for triglycerides (Table 1). Supplementary Table 5
emphasizes that, at these loci, much stronger signals are identified in meta-analysis than in
any component study. Reassuringly, these signals point to loci identified in previous
genome-wide association studies and/or re-sequencing studies. Importantly, note that our
approach was able to appropriately identify the signal in LDLR which is driven by several
very rare variants (each with frequency < .00052) that nearly always increase blood LDL
cholesterol levels and that, at several other loci, gene-level p-values exceeded the best single
variant p-value in the gene (Supplementary Table 6). We again compared our method with
conventional methods such as minimal p-value approach, Fisher's method, and an extended
Fisher's method taking into account unequal sample sizes (Methods). As shown in
Supplementary Tables 7-9, our method identifies a larger number of loci, all known to be
associated with lipid levels in humans. We also compared results obtained from our meta-
analysis method with results from directly pooling a subset of the data (after normal
transformation of trait values in each sample to avoid artifacts due to stratification).
Reassuringly, p-values from our approach and joint analysis of pooled data were highly
concordant with r2>0.99 (Supplementary Figure 12), in accordance with results obtained
using coalescent simulations.
An added convenience of sharing single-variant statistics together with their covariance
matrices, as we propose, is that it facilitates conditional analyses, extending an idea used by
Yang et al28 for analysis of common variants in GWAS meta-analysis. Supplementary
Figure 13 illustrates how, in simulations, common variants can generate shadow rare variant
association signals at nearby genes, and how our method for conditional analysis resolves
the problem. In real data, we re-examined two of the LDL associated loci in detail, LDLR
and APOE-BCAM-CBLC-PVR. For LDLR, we examined the relationship between rare
variant signals and three nearby common variants26. Specifically, we conditioned on
genotypes for 3 common variants (rs6511720, rs2228671 and rs72658855) exhibiting
significant association in the region, and found that LDLR rare variant association remains
significant (p-value 4.6×10-7) (Supplementary Table 10). For the APOE-BCAM-CBLC-PVR
locus, after conditioning on the common variant showing strongest association in the region
(rs7412), gene-level associations at BCAM, CLBC and PVR become non-significant,
suggesting that these rare-variant signals are the result of regional linkage disequilibrium
with more common and well described variants in APOE (Supplementary Table 11). We
also analyzed top single association signal conditional on the genotypes of rare variants
(with MAF≤5%) that are included in the burden tests. We showed that the top single variant
signals from both APOE gene and the LDLR gene remained significant (Supplementary
Table 12). For completeness, Supplementary Figure 14 and 15 show that conditional
analyses using individual level data in a subset of samples and conditional analyses using
our meta-analysis based approach give highly concordant p-values (r2>0.99).
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In the analysis of each sample, when population stratification is of concern, we recommend
that principal components of genotype matrix should be incorporated in the regression
model as covariates29 or that linear mixed models with empirically estimated kinship
matrices should be used30. Linear mixed models can also be used to account for relatedness
in family studies or other samples that include cryptically related individuals. Our software
implementation readily allows for both these options, including correct calculation of
kinship matrices to allow family samples to be included in meta-analyses (see Methods for
details).
Although we only presented applications of our method to quantitative trait meta-analysis,
our methods and tools can be applied to binary traits as well (see Methods for details). For
binary traits, distributions about normality of test statistics may be less reliable. These could
affect performance of our resampling method for empirical p-values, meta-analysis results
for the rarest variants, and conditional analysis statistics (see also the work of Lin and
Tang 9 and Lee et al 31). Since performance of our methods (and other similar approaches)
for binary traits will depend on factors like sample size and the balance of cases and controls
in each sample, we recommend careful quality control of results for such studies, including
for example, review of quantile-quantile plots for variants of different frequencies. Our
methods are implemented as freely available software, including programs for calculating
summary statistics, annotating the resulting summaries, performing meta-analysis,
calculating gene-level statistics and executing conditional analyses. Our tools work with
standard VCF files32 for genotype data and Merlin33 or PLINK34 files for phenotype data.
Meta-analysis has facilitated many discoveries in common variant association studies. Here,
we describe a powerful framework for meta-analysis of rare variants at the level of genes or
other functional units. Through simulation and empirical evaluation, we demonstrate that
our approach is well calibrated and provides comparable power to more cumbersome
analyses that require pooling all individual level data. Through the analysis of blood lipids
levels across seven studies, we show that our approach can detect rare variant association
signals at known candidate loci. Our method has a variety of unique features, which include
supporting a variety of rare variant association tests, allowing for the analysis of family
samples and the calculation of empirical p-values, and for conditional analysis that can
distinguish truly novel rare variant signals from shadows of other nearby common or rare
associations. We envision that this approach (and continued development of related
approaches 35-37) will facilitate the large sample sizes required to accelerate new discoveries
in complex trait genetics.
Methods
This section starts with a summary of notation, proceeds to describe the statistics to be
shared between studies and methods for single variant meta-analysis. We then show that the
statistics for different gene-level tests can be calculated using summary level data, enabling
efficient meta-analysis. In the Supplementary Notes, we provide many additional details and
summarize how each of the test statistics used here can be derived as a score test using
likelihood functions that allow for per-sample nuisance parameters.
Notation
For simplicity, we describe our strategy for analysis of a single gene. Let J be number of
variant nucleotide sites genotyped in at least one study. For study k, let nk denote the number
of samples phenotyped and genotyped, and let the vector yk = (Y1,k,…,YNk,k)T denote the
quantitative trait residuals (after adjustment for any covariates), with variance  . Within
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teach study k, we encode genotype information in matrix Xk where each entry Xi,j,k
represents the genotype for individual i at site j, coded as the number of alternative alleles.
We encode missing genotypes in the dataset as the average number of minor alleles in
individuals who are genotyped for that marker. The multi-site genotype for individual i is
denoted by the row vector xi, •, k, and the genotypes for all Nk individuals at site j are given
by column vector x •,j,k For the ease of presentation, we define the mean genotype matrix
X̄k, where the (i,j)-th element is (ΣiXi,j,k)/Nk.
Summary Statistics To Be Shared
For each study, we first calculate and share a vector of score statistics uk = (Xk − X̄k)T yk, a
corresponding variance-covariance matrix
, and allele frequencies for each marker
pj,k = ΣiXi,j,k/2Nk. Note that Vk effectively describes linkage disequilibrium relationships
between the variants being examined. To perform quality control, we also share mean and
variance for the quantitative trait residuals, genotype call rate and Hardy-Weinberg
equilibrium p-values at each variant site.
Meta-analysis of Single Variant Association Test Statistics
We first combine single variant association test statistics across studies using the Cochran-
Mantel-Haenszel method. Specifically, we calculate a score statistic at each site as:
(1)
where Uj,• = Σk Uj,k and Vj,j,• = Σk Vj,j,k. For ease of presentation, we denote the vector of
single variant association tests after meta-analysis as u = Σk uk. Under the null, this vector is
distributed as multivariate normal with mean vector 0 and covariance matrix Σk Vk.
Burden Tests That Assume Variants Have Similar Effect Sizes
For a simple burden test in study k, the impact of multiple rare variants in a region can be
modeled using a shared regression coefficient in a model that takes the form:
(2)
CBURDEN (xi,•,k) is a function that takes genotypes for a single individual as input and
returns the count of rare alleles (the “rare variant burden”) in the gene being examined.
When individual level data is available and nuisance parameters β0,k and   are allowed to
vary between studies, the score statistic for a rare variant burden test becomes:
(3)
which is equal to a linear sum of (weighted) single variant score statistics.
Under the null, this statistic is approximately normally distributed with mean 0 and variance
VBURDEN = ωT (ΣkVk)ω, enabling significance tests. Here, ω is the vector of weights, which
is ω = (ω1,…, ωj), with each element ωj representing the weight assigned to variant j
according to its allele frequency or its computationally predicted functional impact10,15. The
formula above makes it clear that, when nuisance parameters are allowed to vary between
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tstudies, the same burden score statistics that could be calculated by sharing individual data
can be equivalently calculated using shared summary statistics.
Variable Threshold Tests with an Adaptive Frequency Threshold
In variable threshold test, rare variant burden statistics are calculated for each observed
variant minor allele frequency threshold and significance is evaluated for the maximum of
these statistics. Given a specific variant frequency threshold F we define the resulting
burden score statistic as:
(4)
Here, vF is a vector of indicators where the jth element equals 1 if the pooled minor allele
frequency at variant site j is less than F and zero otherwise. For convenience, we also define
a matrix of indicators for minor allele frequency thresholds Φ = (vF1, vF2, …, vFJ). After a
burden statistic is calculated for each potential frequency threshold, these are standardized,
dividing each statistic by its corresponding variance, and the maximum statistic is identified:
(5)
Significance for this statistic can be evaluated using the cumulative distribution function for
the multivariate normal distribution38. Specifically, given the definition of the covariance
between burden statistics calculated using different allele frequency thresholds, we have:
(6)
The p-value for the VT test statistic is given by
(7)
where FMVN is the distribution function for the multivariate normal distribution
MVN(0,Φ(ΣkVk)ΦT).
Burden Tests that Assume A Distribution of Variant Effect Sizes (e.g. SKAT tests)
The simple burden test and variable threshold test described above can be underpowered
when variants with opposite phenotypic effects reside in the same gene and are grouped
together, because the shared regression coefficient can average close to zero in that
situation9-12. To accommodate this setting, we consider an underlying distribution of rare
variance effect sizes with mean zero and test whether the variance of this distribution τ is
greater than zero.
When individual level data is available, association analysis in study k is performed using
the following model
(8)
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tWe make inferences about rare variant effect sizes β = (β1, β2, … βJ) by assuming these
follow a common distribution with mean zero and variance τ. Under the null, τ=0.
Following Wu et al9, in Supplementary Notes we derive the score statistic for this model and
show that it can be calculated on the basis of per-study summary statistics:
(9)
Here, K is the kernel matrix that compares multi-site genotypes. A default choice9 is a
diagonal matrix K = diag(ω1, ω2 …, ωJ), with ωj being the weight assigned to variant site j.
The statistic Q follows a mixture chi-square distribution31, which means that Q is equivalent
in distribution to a weighted sum of independent chi-square random variables. The weights
(or mixture proportions) are given by the eigenvalues for the matrix (ΣkVk)1/2 K(ΣkVk)1/2.
Monte-Carlo Method for Empirical Assessment of Significance
The previous sections describe how a series of gene-level test statistics can be calculated
and, for each one, propose a strategy for evaluating significance using asymptotic
distributions. In practice, evaluating the required numerical integrals can be challenging
because variance-covariance matrices that are sometimes singular or nearly singular.
Note that single variant test statistics are distributed as:
(10)
Then, to evaluate significance empirically, one can sample random vectors from the
distribution MVN(0, ΣkVk) and calculate gene-level rare variant test statistics for each of
these sampled random vectors, resulting in an empirical distribution for any gene-level
statistic39. As usual, p-values can then be evaluated by comparing the test statistics for the
original data with those in this empirical distribution. For computational efficiency, we use
an adaptive algorithm where a larger number of vectors are sampled when assessing small p-
values and fewer vectors are sampled when assessing larger p-values20.
Conditional Analyses
It is well known that, due to linkage disequilibrium, one or more common causal variants
can result in shadow association signals at other nearby common variants. For common
variants, Yang et al28 have shown that linkage disequilibrium relationships between
variants, estimated from external reference panels, can be used to enable conditional
analysis in meta-analysis settings. For rare variants and gene-level tests, accurately
describing relationships between variants is crucial and we recommend against the use of
external reference panels. Instead, in the Supplementary Notes, we describe how conditional
analysis statistics can be derived for different gene-level tests in our meta-analysis setting.
Analysis of Samples of Known or Hidden Relatedness
Our methods and tools can also be used when samples within a study are related to each
other. Detailed formulae of the score statistics and their covariance matrices when linear
mixed models are used to account for relatedness, are described in the Supplementary Notes.
Analysis of Dichotomous Trait
Our approach extends naturally to the analysis of binary traits. Specifically, when single
variant score statistics and their covariance matrices are shared, meta-analysis test statistics
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statistics for binary traits are given in the Supplementary Notes. A limitation is that, when
variant counts in a gene or analysis unit are very small or the number of cases and controls
in each study is very unbalanced, the asymptotic distributions for burden statistics may not
hold, and p-values obtained using our approach may not be accurate. In practice, we
recommend careful review of QQ plots for meta-analysis statistics (as is standard in
genome-wide association studies).
Weighted Fisher's Methods, Incorporating Unequal Sample Sizes
To accommodate the scenario where samples of different sizes are meta-analyzed, we use a
modified version of Fisher's method that incorporates sample sizes as weights for each
study. Specifically, our test statistic is defined by TWeighted–Fisher = −2ΣkNk log pk. The
weighted Fisher's test statistic follows a mixture chi-square distribution with mixture
proportions given by N1, N1, N2, N2,…,Nk, Nk.
Simulation of Population Genetic Data
We simulated haplotypes using a coalescent model and the program ms16. We chose a
demographic model consistent with European demographic history4, including an ancestral
bottleneck followed by more recent population differentiation and exponential growth.
Model parameters were based upon estimates from large scale sequencing studies40, as
detailed in Supplementary Notes.
Meta-Analysis of Lipid Traits
Summary statistics were calculated for each participating study and shared to enable a
central meta-analysis. In single variant and gene-base rare variant association analysis, age,
age2, sex and cohort specific covariates, such as principal components of ancestry were
included in the analysis. Trait residuals were standardized using inverse normal
transformation. More detailed descriptions for each participating cohort are given in the
Supplementary Notes. This research was approved by the Institutional Review Board of the
University of Michigan and the Broad Institute. Informed consent was obtained from all
study subjects. In addition, all participating studies received approvals from local ethics
committee.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Power comparison for our approach, Fisher's method and the minimal p-value approach.
Three phenotype models were simulated: (1) half of low frequency variants with MAF <
0.5% are causal, each increasing expected trait values by 1/4 standard deviation; (2) half of
all variants are causal, irrespective of frequency, and increase trait values by 1/4 standard
deviation; (3) 50% of the variants are casual, irrespective of frequency, and 80% of these
increase expected trait values by 1/4 standard deviation, while the remaining 20% decrease
trait values by the same amount. A number of 2-100 samples of size 1000 were simulated
for each model, with each sample drawn from a randomly chosen population. Meta-analysis
was performed using our approach or using Fisher's method and the minimal p-value
approach to combine burden test, SKAT and variable threshold (VT) test statistics for
variants with MAF<5%. The power was evaluated at the significance threshold of
α=2.5×10-6 using 10,000 replicates. Panel A displays the power for three meta-analysis
methods using simple burden test under model (1). Panel B displays the results for three
meta-analysis methods using VT under model (1). Panel C displays the results for three
meta-analysis methods using SKAT under model (1). Panel D displays the results for three
meta-analysis methods using simple burden test under model (2). Panel E displays the
results for three meta-analysis methods using VT under model (2). Panel F displays the
results for three meta-analysis methods using SKAT under model (2). Panel G displays the
results for three meta-analysis methods using simple burden test under model (3). Panel H
displays the results for three meta-analysis methods using VT under model (3). Panel I
displays the results for three meta-analysis methods using SKAT under model (3). Note that
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tdifferences between our approach and these alternatives become more marked when more
studies are meta-analyzed.
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